Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.
Commercial priorities have been identified as negative factors in drug development. We trace the problem to inattention to sound clinical pharmacology practices. When properly applied, clinical pharmacology and associated drug development sciences can, hand in hand, facilitate success in commercial drug development.
Becker
Robert E
RE
Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA. rebecker2008@comcast.net
Unni
Latha K
LK
Greig
Nigel H
NH
D000110:Acetylcholinesterase / Q000378:metabolism; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards; D004305:Dose-Response Relationship, Drug; D004345:Drug Industry / Q000379:methods* / Q000592:standards; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D010601:Pharmacology, Clinical / Q000379:methods* / Q000592:standards; D014236:Trichlorfon / Q000008:administration & dosage / Q000494:pharmacology
D002800:Cholinesterase Inhibitors; D014236:Trichlorfon; D000110:Acetylcholinesterase